[go: up one dir, main page]

WO2002036769A3 - Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques - Google Patents

Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques Download PDF

Info

Publication number
WO2002036769A3
WO2002036769A3 PCT/EP2001/012495 EP0112495W WO0236769A3 WO 2002036769 A3 WO2002036769 A3 WO 2002036769A3 EP 0112495 W EP0112495 W EP 0112495W WO 0236769 A3 WO0236769 A3 WO 0236769A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
methods
nucleic acids
acids encoding
chimeric polypeptides
Prior art date
Application number
PCT/EP2001/012495
Other languages
English (en)
Other versions
WO2002036769A2 (fr
Inventor
Frank Dicker
Dirk Moritz
Gerd Maass
Original Assignee
Hoffmann La Roche
Frank Dicker
Dirk Moritz
Gerd Maass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Frank Dicker, Dirk Moritz, Gerd Maass filed Critical Hoffmann La Roche
Priority to AU2002221780A priority Critical patent/AU2002221780A1/en
Publication of WO2002036769A2 publication Critical patent/WO2002036769A2/fr
Publication of WO2002036769A3 publication Critical patent/WO2002036769A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un acide nucléique codant un polypeptide chimérique CD40/CD40L comprenant des fragments d'acide nucléique codant i) le domaine de signalisation de CD40 et en aval de celui-ci, ii) un domaine transmembranaire d'un récepteur de type II et en aval de celui-ci, iii) le domaine de liaison et de trimérisation de CD40L, cet acide nucléique pouvant être utilisé comme agent de thérapie génique pour le traitement local de tumeurs solides.
PCT/EP2001/012495 2000-10-31 2001-10-29 Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques WO2002036769A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002221780A AU2002221780A1 (en) 2000-10-31 2001-10-29 Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00123721 2000-10-31
EP00123721.3 2000-10-31

Publications (2)

Publication Number Publication Date
WO2002036769A2 WO2002036769A2 (fr) 2002-05-10
WO2002036769A3 true WO2002036769A3 (fr) 2003-01-30

Family

ID=8170257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012495 WO2002036769A2 (fr) 2000-10-31 2001-10-29 Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques

Country Status (2)

Country Link
AU (1) AU2002221780A1 (fr)
WO (1) WO2002036769A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2739073C2 (ru) * 2014-04-07 2020-12-21 Локон Фарма Аб Новые медицинские агенты и их применение

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
CA2516320C (fr) * 2003-02-18 2015-05-26 Kevin Slawin Activation induite dans des cellules dendritiques
EP2066339B1 (fr) 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Compositions et procédés pour améliorer des réponses immunes
EP2076272B1 (fr) 2006-10-19 2015-07-29 Baylor College Of Medicine Generation d'une reponse immune en induisant des recepteurs cd40 et des recepteurs de reconnaissance de structures
WO2009059018A1 (fr) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions et procédés pour améliorer les réponses immunitaires dirigées contre une bactérie flagellée
DK3097926T3 (da) 2007-11-01 2019-12-16 Univ Arkansas Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria
ES2633470T3 (es) 2008-09-22 2017-09-21 Baylor College Of Medicine Métodos y composiciones de generación de una respuesta inmune mediante la inducción de CD40 y adaptadores de receptores de reconocimiento de patrones
NO2525817T3 (fr) 2010-01-21 2018-01-06
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
UA113496C2 (xx) 2010-06-09 2017-02-10 Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter
US9603915B2 (en) 2013-02-14 2017-03-28 The Board of Trustees of the University of Akansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
US9944690B2 (en) 2013-03-14 2018-04-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
AU2014274916B2 (en) 2013-06-05 2019-10-31 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
WO2015123527A1 (fr) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Méthodes d'activation des lymphocytes t à l'aide d'un polypeptide chimère inductible
WO2016036746A1 (fr) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation de récepteurs d'antigènes chimériques par des polypeptides dérivés de myd88 et cd40
EP3215522B1 (fr) 2014-11-03 2021-12-01 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Récepteurs de cellules t dirigées contre bob1 et leurs utilisations
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
US11564944B2 (en) 2016-11-21 2023-01-31 Nant Holdings Ip, Llc Fractal combination therapy
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
CN112566926A (zh) * 2018-06-14 2021-03-26 南特生物公司 Tnf型受体-配体融合蛋白及方法
US20210369825A1 (en) * 2018-10-05 2021-12-02 Nantcell, Inc. Cd40 and cd40l combo in an adv vaccine vehicle
AU2020315796A1 (en) * 2019-07-19 2022-02-24 Memorial Hospital For Cancer And Allied Diseases Fusion polypeptide for immunotherapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008207A1 (fr) * 1991-10-25 1993-04-29 Immunex Corporation Nouvelle cytokine
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
WO1998026061A2 (fr) * 1996-12-09 1998-06-18 University Of California Nouveaux vecteurs d'expression contenant des genes de ligands de molecules accessoires et leur emploi a des fins d'immunomodulation et de traitement des tumeurs malignes et des maladies autoimmunes
WO2000063395A1 (fr) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008207A1 (fr) * 1991-10-25 1993-04-29 Immunex Corporation Nouvelle cytokine
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
WO1998026061A2 (fr) * 1996-12-09 1998-06-18 University Of California Nouveaux vecteurs d'expression contenant des genes de ligands de molecules accessoires et leur emploi a des fins d'immunomodulation et de traitement des tumeurs malignes et des maladies autoimmunes
WO2000063395A1 (fr) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2739073C2 (ru) * 2014-04-07 2020-12-21 Локон Фарма Аб Новые медицинские агенты и их применение

Also Published As

Publication number Publication date
AU2002221780A1 (en) 2002-05-15
WO2002036769A2 (fr) 2002-05-10

Similar Documents

Publication Publication Date Title
WO2002036769A3 (fr) Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques
WO2001072957A3 (fr) Molecules de type facteur de croissance des fibroblastes et leurs utilisations
WO1999015654A3 (fr) Homologues du ligand 'tie' du type tyrosine kinase receptrice
WO2002002624A3 (fr) Molecules de type b7 et utilisation de ces molecules
WO2002008285A3 (fr) Molecules il-17 et leurs utilisations
AU2175597A (en) Modulators of tnf receptor associated factor (traf), their preparation and use
IL140938A (en) Dna sequences encoding polypeptides capable of binding to ldcam, polypeptides encoded by them, fusion proteins comprising the polypeptides and a process for the preparation of the polypeptides
WO2000018914A3 (fr) NOUVEAUX POLYPEPTIDES $i(DKR)
IL144952A0 (en) Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
WO2003020932A1 (fr) Nouvelles proteines de secretion et adn associe
WO2002000724A3 (fr) Molecules de recepteur de lymphopoietine de stroma thymique et utilisations de celles-ci
WO2001068854A3 (fr) Molecules s'apparentant au facteur de croissance des fibroblastes et leurs utilisations
WO2001055178A3 (fr) Compositions et methodes de traitement de cancer
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO2001005825A3 (fr) Nouveaux procedes et materiaux des angiopoietines
WO2001068859A3 (fr) Molecules du type recepteur de l'interleukine 17 et leur utilisation
WO2003008446A1 (fr) Polypeptides se rapportant au transfert de signaux de recepteur de produits terminaux a glycation avancee
WO2001068705A3 (fr) Molecules du type recepteur de l'interleukine 17 et leurs utilisations
MXPA01006006A (es) Cadena receptora de citocina.
WO2001042474A3 (fr) Molecules de type interferon et utilisations
WO2002062954A3 (fr) Modulation antisens de l'expression de la caseine kinase 2-beta
WO2001019861A3 (fr) Anticorps du recepteur d'apo-2
WO2002016611A3 (fr) Polypeptides d'interleukine-22, acides nucleiques codant pour lesdits polypeptides et methode permettant de traiter les affections pancreatiques
WO2002062818A3 (fr) Modulation antisens de l'expression de la caseine kinase 2-alpha
WO2001059120A3 (fr) Molecules de type il-17 et utilisation de ces dernieres

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP